| Boceprevir for previously treated chronic HCV genotype 1 infection BR Bacon, SC Gordon, E Lawitz, P Marcellin, JM Vierling, S Zeuzem, ... New England Journal of Medicine 364 (13), 1207-1217, 2011 | 2254 | 2011 |
| Diagnosis and management of autoimmune hepatitis MP Manns, AJ Czaja, JD Gorham, EL Krawitt, G Mieli‐Vergani, D Vergani, ... Hepatology 51 (6), 2193-2213, 2010 | 2003 | 2010 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1124 | 2016 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1081 | 2019 |
| Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection … PY Kwo, EJ Lawitz, J McCone, ER Schiff, JM Vierling, D Pound, MN Davis, ... The Lancet 376 (9742), 705-716, 2010 | 857 | 2010 |
| Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview‐based study of 1032 patients ME Gershwin, C Selmi, HJ Worman, EB Gold, M Watnik, J Utts, KD Lindor, ... Hepatology 42 (5), 1194-1202, 2005 | 741 | 2005 |
| Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases CL Mack, D Adams, DN Assis, N Kerkar, MP Manns, MJ Mayo, JM Vierling, ... Hepatology 72 (2), 671-722, 2020 | 719 | 2020 |
| Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection M Bourlière, SC Gordon, SL Flamm, CL Cooper, A Ramji, M Tong, ... New England Journal of Medicine 376 (22), 2134-2146, 2017 | 650 | 2017 |
| Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence F Poordad, ER Schiff, JM Vierling, C Landis, RJ Fontana, R Yang, ... Hepatology 63 (5), 1493-1505, 2016 | 577 | 2016 |
| Glecaprevir–pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection S Zeuzem, GR Foster, S Wang, A Asatryan, E Gane, JJ Feld, T Asselah, ... New England Journal of Medicine 378 (4), 354-369, 2018 | 484 | 2018 |
| Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’ U Beuers, EM Gershwin, RG Gish, P Invernizzi, DEJ Jones, K Lindor, ... Official journal of the American College of Gastroenterology| ACG 110 (11 …, 2015 | 456 | 2015 |
| Autoimmune hepatitis G Mieli-Vergani, D Vergani, AJ Czaja, MP Manns, EL Krawitt, JM Vierling, ... Nature Reviews Disease Primers 4 (1), 1-21, 2018 | 419 | 2018 |
| Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis MG Ghany, B Ayola, FG Villamil, RG Gish, S Rojter, JM Vierling, AS Lok Hepatology 27 (1), 213-222, 1998 | 405 | 1998 |
| Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre … KV Kowdley, E Lawitz, I Crespo, T Hassanein, MN Davis, M DeMicco, ... The Lancet 381 (9883), 2100-2107, 2013 | 383 | 2013 |
| Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus … M Sulkowski, C Hezode, J Gerstoft, JM Vierling, J Mallolas, S Pol, ... The Lancet 385 (9973), 1087-1097, 2015 | 371 | 2015 |
| Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy RJ Fontana, HWL Hann, RP Perrillo, JM Vierling, T Wright, J Rakela, ... Gastroenterology 123 (3), 719-727, 2002 | 351 | 2002 |
| 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients MC Dubinsky, EA Vasiliauskas, H Singh, MT Abreu, KA Papadakis, T Tran, ... Gastroenterology 125 (2), 298-303, 2003 | 323 | 2003 |
| Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection AJ Muir, ML Shiffman, A Zaman, B Yoffe, A De La Torre, S Flamm, ... Hepatology 52 (3), 822-832, 2010 | 304 | 2010 |
| Acute hepatitis associated with the Chinese herbal product Jin Bu Huan GM Woolf, LM Petrovic, SE Rojter, S Wainwright, FG Villamil, WN Katkov, ... Annals of internal medicine 121 (10), 729-735, 1994 | 273 | 1994 |
| Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension N Chalasani, MF Abdelmalek, G Garcia-Tsao, R Vuppalanchi, N Alkhouri, ... Gastroenterology 158 (5), 1334-1345. e5, 2020 | 258 | 2020 |
